Jason Baum - Apr 1, 2023 Form 3 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Role
Chief Scientific Officer
Signature
/s/ Douglas E. Onsi as attorney-in-fact for Jason Baum
Stock symbol
LPTX
Transactions as of
Apr 1, 2023
Transactions value $
$0
Form type
3
Date filed
4/3/2023, 07:49 PM
Next filing
Aug 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LPTX Employee Stock Option (Right to Buy) Apr 1, 2023 Common Stock 75K $1.97 Direct F1
holding LPTX Employee Stock Option (Right to Buy) Apr 1, 2023 Common Stock 50K $2.57 Direct F2
holding LPTX Employee Stock Option (Right to Buy) Apr 1, 2023 Common Stock 30K $1.62 Direct F3
holding LPTX Employee Stock Option (Right to Buy) Apr 1, 2023 Common Stock 200K $1.43 Direct F4
holding LPTX Restricted Stock Units Apr 1, 2023 Common Stock 225K $0.00 Direct F5, F6
holding LPTX Employee Stock Option (Right to Buy) Apr 1, 2023 Common Stock 500K $0.34 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option was granted on August 10, 2020 pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option became vested and exercisable for 25% of the shares underlying the Option on August 10, 2021 and vests and becomes exercisable for the remaining shares in a series of 36 equal monthly installments thereafter for so long as the reporting person continues to be employed by or provides service to the Company.
F2 The Option was granted on January 26, 2021 pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option vests and becomes exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments having become vested on February 26, 2021.
F3 The Option was granted on May 26, 2021 pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option vests and becomes exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments having become vested on June 26, 2021.
F4 The Option was granted on September 1, 2022 pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option vests and becomes exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments having become vested on October 1, 2022.
F5 The Restricted Stock Units were granted on January 31, 2022 pursuant to Leap's 2016 Equity Incentive Plan and will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.
F6 No consideration was or will be paid or provided by the reporting person in connection with the grant or award of the Restricted Stock Units or the issuance of the shares of Common Stock underlying the Restricted Stock Units upon settlement thereof.
F7 The Option was granted on March 31, 2023 pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option vests and becomes exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on April 30, 2023.

Remarks:

Exhibit 24.1 Power of Attorney